VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of
News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was
VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027
AUSTIN, Texas, Sept. 3, 2026 /CNW/ -- Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug
VANCOUVER, Wash. and NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it
Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents,
Issued on behalf of MindWalk Holdings Corp. (NASDAQ:HYFT)AUSTIN, Texas, July 24, 2026 /CNW/ -- American News Group News Commentary - The race to bring artificial intelligence into drug discovery has become one of the
Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today
Issued on behalf of MindWalk Holdings Corp.MindWalk Holdings Corp. (NASDAQ:HYFT) filed a European patent application directed to the high-dimensional biological data architecture beneath its HYFT® Technology, ReefIQ™,
A wave of government funding, hardware progress, and looming encryption deadlines has turned quantum from a lab curiosity into one of the most closely watched corners of the market in 2026, spanning computing hardware
Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of
